Elsevier

Biomaterials

Volume 134, July 2017, Pages 31-42
Biomaterials

Molecular imaging of activated platelets via antibody-targeted ultra-small iron oxide nanoparticles displaying unique dual MRI contrast

https://doi.org/10.1016/j.biomaterials.2017.04.037Get rights and content

Abstract

Magnetic resonance imaging (MRI) is a powerful and indispensable tool in medical research, clinical diagnosis, and patient care due to its high spatial resolution and non-limited penetration depth. The simultaneous use of positive and negative MRI imaging that employs the same contrast agents will significantly improve detection accuracy. Here we report the development of functional multimodal iron oxide nanoparticles for targeted MRI of atherothrombosis using a combination of chemical and biological conjugation techniques. Monodisperse, water-soluble and biocompatible ultra-small magnetic dual contrast iron oxide nanoparticles (DCIONs) were generated using a high-temperature co-precipitation route and appeared to be efficient positive and negative dual contrast agents for magnetic resonance imaging. Using a unique chemo-enzymatic approach involving copper-free click chemistry and Staphylococcus aureus sortase A enzyme conjugation, DCIONs were functionalized with single-chain antibodies (scFv) directed against activated platelets for targeting purposes. The DCIONs were also labelled with fluorescent molecules to allow for optical imaging. The antigen binding activity of the scFv was retained and resulted in the successful targeting of contrast agents to thrombosis as demonstrated in a range of in vitro and in vivo experiments. T1- and T2-weighted MRI of thrombi was recorded and demonstrated the great potential of dual T1/T2 contrast iron oxide particles in imaging of cardiovascular disease.

Introduction

Despite significant advances in diagnostic and therapeutic technologies, cardiovascular disease (CVD) remains the global leading cause of death, accounting for 17.3 million deaths per year, and is expected to grow to more than 23.6 million by 2030 [1]. This represents 30% of all global deaths and 80% of this occurs in low- and middle-income countries. CVD claims more lives than all forms of cancers combined [1]. Of all CVDs, stroke and coronary artery disease account for more than 70% of all deaths [2].

The most common form of CVD and also the leading cause of sudden death is atherosclerosis, a chronic progressive inflammatory disease of the arterial vessels. The process of atherosclerosis involves a complex interplay between various cells, particular leukocytes and platelets [3]. Unstable, vulnerable atherosclerotic plaques can rupture and cause thrombosis, resulting in myocardial infarction (MI) and stroke. Recent studies have confirmed that (micro)thrombi containing activated platelets exist long before the presentation of sudden coronary death, indicating that vessel occlusion is often preceded by a variable period of localized coagulation and inflammation [4]. Currently, the prevention of MI and stroke is limited due to the lack of sensitive imaging methods. Those available usually involve invasive procedures such as coronary angiograms, which are potentially associated with complications, including death caused by MI or bleeding. Hence, there is a great need for new diagnostic strategies to determine whether the individual patient is at risk of MI or stroke, which then would allow for effective and early preventative treatment and improved clinical outcome.

Molecular imaging, the non-invasive visualization of fundamental (disease) biomarkers in living organisms, holds the promise to transform the diagnosis of CVD, profoundly impacting future clinical CVD care. Non-invasive detection of thrombosis employs various contrast agents that are equipped with moieties targeting the biological features associated with thrombosis formation such as fibrin, factor XIII, and activated platelets [5], [6]. Compared to other modalities, molecular MRI has great potential for thrombus detection. Unlike positron emission tomography (PET) or computed tomography (CT) methods, MRI does not employ ionizing radiation; unlike ultrasound and optical methods, MRI provides deep tissue penetration; and it is more advantageous than PET, because MRI has much higher spatial resolution (sub-millimeter). The principle drawback of molecular MRI is the lower sensitivity of contrast agent detection compared to nuclear techniques and therefore the choice of a highly abundant target and the design of sensitive and specific molecular probes are critical. For molecular imaging of thrombosis, platelets are an ideal choice for targeting since they are the major component of thrombi [7].

To achieve high accuracy of disease diagnosis, attempts to combine complementary information obtained from different imaging techniques, including MRI, PET, CT and optical microscopy [8], [9], [10], [11] have been made. However, differences in depth penetrations and spatial/time resolutions of various imaging devices can lead to difficulties and discrepancies when matching images, resulting in interpretation inaccuracies [8], [9]. The development of dual imaging strategies that employ a single imaging technique and a single instrumental system such as MRI would provide significant advantages.

There are two widely used T1 and T2/T2* - weighted MRI contrast agents. Gadolinium (Gd) based agents enhance signal due to T1 shortening at lower concentrations providing positive image contrast. At high concentrations, e.g. in the bolus following injection, Gd agents null the signal due to T2/T2* shortening. Iron oxide nanoparticles generally provide negative image contrast due to T2/T2* shortening. The T1 effect or bright spot imaging is preferred since the location of the imaging agent is more readily distinguishable from potential artefacts produced by tissue interfaces, hemorrhage or signal cancellations at water-fat interfaces, which all produce negative contrast effects [12]. T1-weighted imaging is particularly advantageous in imaging of vessel thrombosis, as a sufficient T1 shortening effect allows generation of positive contrast between a thrombus (appearing bright in the image) and surrounding tissues and blood (dark). T2-contrast agents, such as magnetic iron oxide nanoparticles, have shown limited toxicity and have been proven to be one of the most promising contrast agents for clinical use because iron is naturally found in the body [13]. These agents can be detected at a relative lower concentration and a sub-millimeter areas using T2-weighted or T2* (susceptibility) weighted imaging. However, the limitations of iron oxide agents include the lack of specificity in heterogeneous anatomy and potential confusion with effects from bleeding, calcification, metal deposits (such as endogenous iron) and other susceptibility artefacts [14].

Previously, several attempts have been reported on the development of MRI imaging agents for molecular imaging of atherosclerosis and thrombosis. Among these, Gd-based agents were widely employed to image endothelial dysfunction and activation [15]; extracellular matrix (ECM - the major component of atherosclerostic lesions) via targeting ECM proteins such as collagen [16], neovascularization by targeting the αvβ3 integrin [17]: proteolytic enzymes during plaque development [18]; thrombus and plaque by targeting fibrin [19], [20], [21], [22], [23], [24]; and lipids – the major components of atherosclerotic plaques [25], [26]. Iron oxide nanoparticles were also used extensively to image endothelial dysfunction by targeting the expressed adhesion molecules on the endothelial surface [27]; macrophages resident in the plaques [28], [29]; and thrombus via targeting GPIIb/IIIa receptors expressed on activated platelets [30], [31], [32]. Although research on molecular imaging of CVD has been reported extensively, these MR imaging agents used only single imaging modes such as T1- or T2/T2*-weighted imaging.

Since both T1-positive and T2-negative contrast agents have their respective advantages and disadvantages, it is highly desirable to prepare a robust dual contrast agent for overcoming the limitations of single modality contrast agents. The simultaneous use of a contrast agent that can provide both T1 and T2 effects will significantly improve detection accuracy. Previously, we have reported the synthesis of ultra-small, water-soluble and biocompatible magnetic iron oxide nanoparticles as positive and negative dual contrast agents [13]. Here we report the development and functionalization of these nanoparticles for targeted imaging of thrombosis. The nanoparticles were also labelled with near infrared dyes to enable optical detection, and functionalized with single-chain antibodies (scFv) for targeting to activated platelets, which are critical players in atherosclerosis, thrombosis, and inflammation [33], [34]. Our strategic approach employing a dual mode, where two different T1 and T2-weighted imaging are performed simultaneously, can potentially provide highly sensitive and accurate diagnostic information.

Section snippets

Materials and methods

All reagents and solvents were obtained from standard commercial sources and were used as received.

Results and discussion

The present work is the first report on imaging of cardiovascular disease or thrombosis using MRI dual positive and negative 3.3 nm iron oxide contrast agents (DCIONs). The scFv-tagged DCIONs were prepared using a unique chemo-enzymatic approach involving copper-free click chemistry and Staphylococcus aureus sortase A enzyme conjugation. The antigen binding activity of the scFv-DCIONs was evaluated in a range of in vitro and in vivo experiments, including binding to in vitro human thrombi and

Conclusion

In conclusion, the presented data demonstrate a successful and unique approach for MR molecular imaging of thrombosis via a dual mode strategy employing positive and negative contrast iron oxide nanoparticles. DCIONs were functionalized and tagged with scFv using a combination of chemical and biological techniques. The conjugation was achieved with a high yield (94%) and a preserved scFv bioactivity was confirmed. The targeting of scFvantiGPIIb/IIIa-tagged DCIONs to activated GPIIb/IIIa

Acknowledgements

This work is funded by National Health and Medical Research Council (H.T.T: APP1037310), University of Queensland Early Career Grant (H.T.T.: UQECR1606713), the Australian Research Council (A.K.W.: CE140100036, K.P.: FT0992210), the National Heart Foundation (C.E.H: CR 11M 6066, X.W: 100517), and the National Natural Science Foundation of China (Z.L.: 81471657 and 81527901). The authors would like to acknowledge the Australian National Fabrication Facility (Queensland Node); National Imaging

References (64)

  • G.K. Hansson

    Inflammation, atherosclerosis, and coronary artery disease

    N. Engl. J. Med.

    (2005)
  • K.L. Ciesienski et al.

    Molecular MRI of thrombosis

    Curr. Cardiovasc Imaging Rep.

    (2010)
  • D. von Elverfeldt et al.

    Dual-contrast molecular imaging allows noninvasive characterization of myocardial ischemia/reperfusion injury after coronary vessel occlusion in mice by magnetic resonance imaging

    Circulation

    (2014)
  • M.F. Kircher et al.

    A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation

    Cancer Res.

    (2003)
  • M. Nahrendorf et al.

    Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis

    Circulation

    (2008)
  • J. Cheon et al.

    Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology

    Acc. Chem. Res.

    (2008)
  • J. Gao et al.

    Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications

    Acc. Chem. Res.

    (2009)
  • A. Phinikaridou et al.

    Molecular MRI of atherosclerosis

    Molecules

    (2013)
  • Z. Li et al.

    Ultrasmall water-soluble and biocompatible magnetic iron oxide nanoparticles as positive and negative dual contrast agents

    Adv. Funct. Mater.

    (2012)
  • J.W. Bulte et al.

    Iron oxide MR contrast agents for molecular and cellular imaging

    NMR Biomed.

    (2004)
  • A. Phinikaridou et al.

    Noninvasive magnetic resonance imaging evaluation of endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent

    Circulation

    (2012)
  • M.R. Makowski et al.

    Assessment of atherosclerotic plaque burden with an elastin-specific magnetic resonance contrast agent

    Nat. Med.

    (2011)
  • P.M. Winter et al.

    Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis

    Arterioscler. Thromb. Vasc. Biol.

    (2006)
  • J.A. Ronald et al.

    Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques

    Circulation

    (2009)
  • X. Yu et al.

    High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent

    Magn. Reson Med.

    (2000)
  • S. Flacke et al.

    Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques

    Circulation

    (2001)
  • R.M. Botnar et al.

    In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent

    Circulation

    (2004)
  • R.M. Botnar et al.

    In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent

    Circulation

    (2004)
  • E. Spuentrup et al.

    Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent

    Circulation

    (2005)
  • M. Sirol et al.

    Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging

    Circulation

    (2004)
  • J.C. Frias et al.

    Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques

    J. Am. Chem. Soc.

    (2004)
  • M. Nahrendorf et al.

    Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis

    Circulation

    (2006)
  • Cited by (0)

    1

    Equal contribution.

    2

    Equal contribution.

    View full text